10-Q: Spectral AI Reports Q2 2026 Results, FDA Clearance Boosts Outlook

Spectral AI, Inc. announced its Q2 2026 financial results, highlighting FDA De Novo classification for its DeepView System, while revenue declined and net loss widened.

Summary

• Spectral AI, Inc. reported its Q2 2026 results, showing a decrease in revenue and an increase in net loss compared to the prior year.
• The company received FDA De Novo classification for its DeepView System on May 26, 2026, enabling commercial distribution in the U.S.
• Revenue for the three months ended June 30, 2026, was $3.5 million, a 30.4% decrease from $5.1 million in the same period of 2025.
• Net loss for the three months ended June 30, 2026, was $4.2 million, compared to a net loss of $8.0 million for the same period in 2025.
• As of June 30, 2026, the company had $14.0 million in cash and cash equivalents.
• The company expects to generate its first commercial sales in the U.S. by the end of 2026 and in the UK during 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative sentiment due to the significant decrease in revenue and widening net loss, despite the FDA De Novo classification. The company's liquidity remains a concern, with a need for future capital raises.

Positives

• FDA De Novo classification granted for the DeepView System on May 26, 2026, allowing for commercial distribution in the United States.
• Received accelerated funding of approximately $31.7 million from BARDA in March 2026.
• The company has sufficient working capital to fund operations for at least one year beyond the release date, based on current operating plans.
• The DeepView System has shown superiority in sensitivity and met non-inferiority margin in specificity compared to clinician assessment in validation studies.
• The company has secured significant government funding, with approximately $282.5 million awarded since 2013, primarily from BARDA.

Negatives

• Revenue for the three months ended June 30, 2026, decreased by 30.4% to $3.5 million compared to $5.1 million in the prior year.
• Net loss for the three months ended June 30, 2026, was $4.2 million, a significant increase from $8.0 million in the prior year.
• Gross margin decreased by 13.6 percentage points to 31.6% for the three months ended June 30, 2026, compared to the prior year.
• Operating expenses increased by 23.1% to $5.4 million for the three months ended June 30, 2026, compared to $4.4 million in the prior year.
• The company has an accumulated deficit of $63.4 million as of June 30, 2026.
• Debt outstanding increased to $14.9 million as of June 30, 2026, from $8.4 million as of December 31, 2025.

Risks

• The company is highly dependent on continued U.S. government contract awards, and any inconsistency in timing or amount could impact results.
• Future operating expenses are expected to increase with commercialization activities, potentially impacting profitability.
• Supply chain disruptions, component shortages, and longer lead times could delay manufacturing and impact cash flows and results.
• The company may need to raise additional capital on unfavorable terms or at all, which could hinder the execution of business plans.
• The company's ability to draw on its shelf registration statement is limited by its public float and market price.

Future Outlook

The company expects to generate its first commercial sales in the United States by the end of 2026 and begin commercialization activities in the United Kingdom in 2026. Pricing for the SaMD and imaging device components will be evaluated and strategically set per country and site-of-service.

Management Comments

• The FDA De Novo classification for the DeepView System is a significant milestone, authorizing the Company to commence commercial distribution activities in the United States.
• The BARDA contract modification provides accelerated funding and validates the important nature of our mission and technology.
• We believe our cash and cash equivalents, together with commitments under the PBS BARDA Contract, and availability under the Yorkville SEPA, provide sufficient working capital to fund operations for at least one year beyond the release date.

Industry Context

StockSavvy.ai notes that the medical diagnostics AI sector is rapidly evolving, with regulatory approvals like the FDA De Novo classification being critical for market entry. Spectral AI's focus on predictive diagnostics for wound healing addresses a significant unmet need, but competition and the path to commercialization remain key challenges.

Comparison to Industry Standards

• The company's revenue streams are currently heavily reliant on government contracts (BARDA, MTEC), which is common for early-stage medical technology companies seeking validation and funding.
• The FDA De Novo pathway is a less common but viable route for innovative medical devices, indicating the novelty of Spectral AI's technology.
• The company's approach to revenue generation, with a planned SaMD (SaaS) model and imaging device component, aligns with industry trends towards recurring revenue and platform-based solutions.

Legal Proceedings

• The Company is not a party to any material legal proceedings or pending claims.

Related Party Transactions

• For the six-month period ended June 30, 2026, the Company did not have any related party transactions.

Stakeholder Impact

• Shareholders may experience volatility due to the widening net loss and the potential need for future capital raises.
• Employees may face uncertainty regarding future funding and operational expansion.
• Government agencies (BARDA, MTEC) are key partners and customers, with ongoing contracts influencing revenue and development.
• Suppliers and contract manufacturers are critical for production, and potential supply chain disruptions could impact operations.

Next Steps

• Commence commercial distribution activities in the United States following FDA De Novo classification.
• Begin commercialization activities in the United Kingdom in 2026.
• Generate first commercial sales in the United States by the end of 2026.
• Continue to fund $9.7 million of the total overall development costs associated with feature advancements under the BARDA contract.
• Conduct health economic and outcome research studies to support broader clinical adoption of the DeepView System.

Key Dates

Recommendation

The FDA De Novo classification is a significant positive catalyst, but the declining revenue, widening net loss, and ongoing liquidity concerns warrant a cautious approach. Investors should monitor commercialization progress and future funding rounds.

Keywords

AI diagnostics, medical device, FDA approval, burn wound, BARDA contract, predictive diagnostics, spectral imaging, De Novo classification